ASTELLAS PHARMA KOREA, INC.
Clinical Trials
20
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT06902545
- Locations
- 🇰🇷
KR82008, Suwon, Gyeonggi-do, Korea, Republic of
🇰🇷KR82006, Yangsan, Gyeongsangnam-do, Korea, Republic of
🇰🇷KR82001, Seoul, Korea, Republic of
Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT06452212
- Locations
- 🇰🇷
KR82001, Seoul, Korea, Republic of
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
- Conditions
- Urothelial Cancer
- Interventions
- Drug: Enfortumab Vedotin
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 235
- Registration Number
- NCT06011954
- Locations
- 🇰🇷
Site KR82001, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Site KR82012, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Site KR82008, Suwon-si, Gyeonggi-do, Korea, Republic of
A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation
- Conditions
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT04691648
- Locations
- 🇰🇷
Site KR82013, Wonju-si, Gangwon-do, Korea, Republic of
🇰🇷Site KR82006, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Site KR82003, Jeollanam-do, Hwasun-gun, Korea, Republic of
A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03737708
- Locations
- 🇰🇷
Site KR82003, Daegu, Korea, Republic of
🇰🇷Site KR82007, Daegu, Korea, Republic of
🇰🇷Site KR82006, Daejeon, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- Next